GE HealthCare is making waves at this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, showcasing its commitment to the future of precision care. The company is highlighting its innovative portfolio of theranostics-enabling solutions, designed to propel clinical and operational excellence in the field.
Among the key announcements is the debut of GE HealthCare’s MIM Software’s LesionID Pro. This AI-powered software introduces automated zero-click pre-processing, streamlining the workflow for physicians. The aim is to minimize the manual segmentation required to glean patient-specific insights, which is crucial for delivering precision care with confidence.
With cancer claiming over 10 million lives globally each year, the rise of precision care, particularly theranostics, offers renewed hope to patients. This approach combines advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, enabling a personalized, patient-centric strategy. This may lead to improved disease detection, treatment accuracy, and overall quality of life.
“Precision care is the future of oncology—and theranostics is at the heart of that future,” says Dr. Shyam Srinivas, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. “The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice. With tools like GE HealthCare’s Omni Legend, StarGuide, and MIM software at our disposal, we can now visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry – ultimately helping improve outcomes for our patients. This is precision care in action, and it’s making a real difference in patients’ lives.”
Molecular imaging, like positron emission tomography (PET) and single photon emission computed tomography (SPECT), is central to theranostics. It provides detailed, patient-specific insights to guide and monitor treatment. However, accessing this data, such as whole-body tumor burden, has historically involved time-consuming manual analysis, creating operational challenges.
GE HealthCare’s MIM Software’s LesionID Pro, with its automated zero-click pre-processing, addresses this. The AI-powered automation is designed to allow physicians easy access to reliable whole-body tumor burden statistics, reducing the need for hours spent manually segmenting lesions.
The new version of LesionID Pro also incorporates significant algorithm improvements, offering physicians precise whole-body tumor volume metrics for review and finalization. These intuitive and user-friendly tools were designed with input from leading theranostics practitioners, to make whole-body tumor burden analysis a practical clinical reality for physicians.
“At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,” states Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. “We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient’s entire care journey—from the imaging equipment needed for a noninvasive look at a patient’s anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.”
GE HealthCare is also showcasing other innovations at #SNMMI25. These solutions are part of a broader portfolio aimed at driving clinical and operational excellence in theranostics. Highlights include:
* MINItrace Magni, GE HealthCare’s newest cyclotron technology, which is designed with a small footprint (about the size of a commercial refrigerator). Its goal is to provide an easy-to-site, easy-to-install solution for producing commercial PET tracers and radiometals, including Gallium-68. This supports personalized care plans.
* Omni Legend, a performance-focused PET/CT designed to evolve and meet healthcare system demands, allowing clinicians to reduce dose by up to 40% while maintaining exceptional image quality. This system continues to gain in popularity, representing the company’s fastest-ever-selling PET/CT.
* StarGuide, a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system helps clinicians pinpoint lesion characteristics and monitor therapy with precision.
* Aurora, an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities and streamlined workflows, offering excellent image quality and operational efficiency. Its CT has a 40 mm detector and the ability to reduce the dose by up to 82%.
* Theranostics Pathway Manager Tile, an application available on GE HealthCare’s Command Center software. It’s designed to simplify the coordination of the theranostics care pathway. It does so by tracking patient readiness for therapy.
“Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,” says Dr. Erik Mittra, professor of diagnostic radiology in at Oregon Health & Science University.
GE HealthCare is positioned to provide solutions at every step of the theranostics care pathway. Its integrated portfolio offers clinicians the isotopes, imaging, informatics, and molecular imaging agents needed to advance precision care.
For details, visit gehealthcare.com. Attendees at SNMMI are also encouraged to visit GE HealthCare’s booth at the New Orleans Ernest N. Morial Convention Center from June 21-24.
**About GE HealthCare Technologies Inc.**
GE HealthCare is a leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. They aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier. With over 125 years serving patients and providers, GE HealthCare is advancing personalized, connected, and compassionate care. Their Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. GE HealthCare is a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit https://www.gehealthcare.com for more information.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/3032.html
